EFS of the DUO System for Tricuspid Regurgitation

Not Applicable

Recruiting

• Conditions: Tricuspid Valve Insufficiency; Heart Valve Diseases; Tricuspid Valve Disease; Tricuspid Regurgitation
• Interventions: Device: DUO Transcatheter Tricuspid Coaptation Valve System

• Registration Number: NCT05913908
• Lead Sponsor: CroiValve Limited

Brief Summary

The study is an early feasibility study to measure individual patient clinical outcomes and effectiveness, evaluate the safety and function of the DUO Transcatheter Tricuspid Coaptation Valve System (DUO System).

Detailed Description

Multi-center, prospective, non-randomized, investigational, and pre-market. Data collected in this clinical study will include safety and function of the investigational system as well as up to 5 year clinical outcomes.

Study Timeline

• Study First Submitted: 2023-05-31
• Study First Submitted QC: 2023-06-12
• Study First Posted: 2023-06-22
• Study Start: 2024-08-13
• Status Verified: 2025-04
• Last Update Submitted: 2025-04-17
• Last Update Posted: 2025-04-22
• Primary Completion: 2025-12
• Study Completion: 2029-10

Recruitment & Eligibility

• Status: RECRUITING
• Sex: All
• Target Recruitment: 15

Inclusion Criteria

1. Presence of severe or greater tricuspid regurgitation as determined by the Echo Core Lab.
2. Patient is symptomatic despite medical therapy.
3. The local Site Heart Team determines the Patient is appropriate for transcatheter valve intervention.
4. The Patient's anatomy is suitable in the judgment of the Patient Selection Committee.
5. Age ≥18 years
6. The Patient has been informed of the nature of the study and agrees to its provisions and has provided written Informed Consent.

Exclusion Criteria

1. Patient is currently participating in another clinical investigation that could affect the outcome of this trial.
2. Any previous tricuspid valve intervention that would interfere with the placement of the investigational device.
3. Moderate or greater tricuspid valve stenosis.
4. Severe aortic, mitral and/or pulmonic valve stenosis and/or regurgitation
5. Pacemaker or implantable cardioverter-defibrillator (ICD) leads that would prevent appropriate placement of the investigational device.
6. Need for concomitant surgical or interventional procedure, known at the time of screening (e.g., CABG, Atrial Septal Defect (ASD) repair).
7. Ejection Fraction (EF) <25%
8. Echocardiographic evidence of unstable intracardiac mass, thrombus or vegetation
9. Patient has Systolic Pulmonary Pressure (sPAP) >60 mm Hg
10. Severe hemodynamic instability: cardiogenic shock or the need for inotropic support or Intra-Aortic Balloon Pump (IABP) or other percutaneous ventricular assist devices
11. Severe respiratory instability with continuous use of home oxygen
12. Severe right ventricular dysfunction
13. Untreated clinically significant coronary or carotid artery disease requiring revascularization surgical or interventional PCI.
14. Stroke or transient ischemic event within 90 days prior to the index procedure
15. Acute myocardial infarction within 30 days before the index procedure
16. Renal insufficiency (eGFR <25 ml/min) or currently on chronic dialysis
17. Active endocarditis within 6 months of the index procedure
18. Pulmonary embolism or deep vein thrombosis within the last 6 months
19. Any surgical, interventional, or transcatheter procedure within 30 days prior to the index procedure
20. Hypertrophic cardiomyopathy, restrictive cardiomyopathy or constrictive pericarditis
21. Life expectancy <1 year
22. Active infections requiring current antibiotic therapy
23. Known severe liver disease
24. Is on the waiting list for a transplant or has had a prior heart or lung transplant
25. Known active peptic ulcer or active GI bleed
26. Unable to take anticoagulant therapy
27. Any known major coagulation abnormalities, thrombocytopenia, platelets < 50,000/ml or severe anemia Hb <8 g/dl
28. Known patient is actively abusing drugs
29. Any known sensitivities or allergies to contrast (that cannot be adequately premedicated) and/or the device materials, including nickel and titanium
30. Patients who are pregnant or intend to become pregnant
31. Any condition making it unlikely the Patient will be able to complete all protocol procedures (including compliance with optimal medical therapy and immobility that would prevent completion of 6MWT), follow-up visits, or impact the scientific soundness of the clinical investigation result

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
Treatment	DUO Transcatheter Tricuspid Coaptation Valve System	Treatment with the DUO Transcatheter Tricuspid Coaptation Valve System (DUO System)

Primary Outcome Measures

Name	Time	Method
Freedom from device or procedure related MAEs	At 30 days	* Death; * Reintervention; * Disabling stroke; * Myocardial infarction; * Major access site and vascular complications; * Severe bleeding; * Renal failure requiring dialysis; * Major cardiac structural complications; * Pulmonary embolism

Trial Locations

Locations (12)

Ascension Via Christi Research; 🇺🇸 Wichita, Kansas, United States

University of Washington; 🇺🇸 Seattle, Washington, United States

Uniwersytetem Medycznym im. Karola Marcinkowskiego w Poznaniu; 🇵🇱 Poznan, Poland

Narodowym Instytutem Kardiologii Stefana Kardynała Wyszyńskiego - Państwowym Instytutem Badawczym; 🇵🇱 Warsaw, Poland

Intermountain Health; 🇺🇸 Salt Lake City, Utah, United States

Los Robles Hospital & Medical Center; 🇺🇸 Thousand Oaks, California, United States

Piedmont Heart Institute; 🇺🇸 Atlanta, Georgia, United States

Northwestern University; 🇺🇸 Chicago, Illinois, United States

Allina Health Minneapolis Heart Institute Foundation; 🇺🇸 Minneapolis, Minnesota, United States

Montefiore Medical Center; 🇺🇸 Bronx, New York, United States

Columbia University Medical Center/NYPH; 🇺🇸 New York, New York, United States

UPMC Pinnacle Harrisburg; 🇺🇸 Harrisburg, Pennsylvania, United States